Moving to a publicly-funded, single-payer system for prescription drugs could save Canada billions of dollars, finds a study by The Mowat Centre.
Genetic testing can significantly improve treatment strategies, but it also raises issues for plan sponsors and members
Maneuvering through treatment plans can be challenging for plan members who are both managing a chronic health condition and have been prescribed a specialty biologic drug. Accessing and administering the drug and dealing with layers of approvals and coverage can seem confusing and arduous in the beginning.
Hepatitis C may not be on your radar as a drug plan sponsor. But with the benefits—and costs—of new therapies, it will be. Globally, there are 200 million people infected with hepatitis C. There’s a high burden of illness in developing countries such as Africa due to “medical misadventure” such as using unsterilized needles, explained […]
Costs are increasing for drug plan sponsors…but not the ones you think.
Drugs continue to be a cost driver for benefits plans, so what should plan sponsors expect going forward?
Equitable Life of Canada is partnering with Rexall to launch a pilot program to mitigate the impact of high-cost specialty drugs for plan sponsors.
Drug plan stakeholders discuss cost management and patient needs at the 2014 Toronto Face to Face Drug Plan Management Forum
The average cost increase for employer-sponsored medical plans globally will dip slightly in 2015 but continue to significantly exceed general inflation levels, says Aon Hewitt.
ClaimSecure has signed a definitive agreement with Janssen to deliver cost-saving programs and solutions to its health benefit plan sponsor clients, excluding Quebec.